Compare Logitech International SA (LOGI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Novartis AG — how do they compare? Logitech International SA trades at $103.79 (market cap $15.18B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 19.6× Logitech International SA's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| LOGI | NVS | |
|---|---|---|
Market Cap | $15.18B | $298.18B |
Sector | Technology | Health |
52-Week High | $126.69 | $168.62 |
52-Week Low | $85.84 | $119.31 |
Enterprise Value | $13.52B | $339.50B |
Dividend Yield | 1.62% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $106.33, up 3.26% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue is projected to grow to $4.9B in 2026, with net income margin improving to 16.27%. The company faces near-term supply chain risks from a key semiconductor supplier shutdown, but strong demand in gaming and premium devices supports growth.
The outlook is mixed: solid fundamentals and analyst consensus target of $109.75 suggest upside, but supply constraints and mixed analyst ratings (26% Buy, 47% Hold, 26% Sell) indicate caution. Investors should weigh robust profitability against operational risks in the coming quarters.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
